Cytek Biosciences, Inc. (CTKB) Financial Statements (2025 and earlier)
Company Profile
| Business Address |
47215 LAKEVIEW BOULEVARD FREMONT, CA 94538 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 3826 - Laboratory Analytical Instruments (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |||
|---|---|---|---|---|---|---|
| ASSETS | ||||||
| Current Assets | ||||||
| Cash, cash equivalents, and short-term investments | 167,299 | 296,601 | 364,618 | |||
| Cash and cash equivalent | 167,299 | 296,601 | 364,618 | |||
| Restricted cash and investments | 331 | 2,899 | ||||
| Receivables | 55,928 | 48,864 | 29,760 | |||
| Inventory, net of allowances, customer advances and progress billings | 60,877 | 48,154 | 32,171 | |||
| Inventory | 60,877 | 48,154 | 32,171 | |||
| Prepaid expense | 9,800 | 6,526 | 4,206 | |||
| Other current assets | 2,230 | 3,796 | 708 | |||
| Other undisclosed current assets | 95,595 | 47,180 | 270 | |||
| Total current assets: | 392,060 | 454,020 | 431,733 | |||
| Noncurrent Assets | ||||||
| Operating lease, right-of-use asset | 10,853 | 13,883 | ||||
| Property, plant and equipment | 18,405 | 13,682 | 5,851 | |||
| Long-term investments and receivables | 1,600 | 1,600 | ||||
| Long-term investments | 1,600 | 1,600 | ||||
| Intangible assets, net (including goodwill) | 39,267 | 14,475 | 14,883 | |||
| Goodwill | 16,183 | 10,144 | 10,144 | |||
| Intangible assets, net (excluding goodwill) | 23,084 | 4,331 | 4,739 | |||
| Other noncurrent assets | 3,385 | 2,957 | 1,665 | |||
| Other undisclosed noncurrent assets | 28,887 | 18,859 | 9,173 | |||
| Total noncurrent assets: | 102,397 | 65,456 | 31,572 | |||
| TOTAL ASSETS: | 494,457 | 519,476 | 463,305 | |||
| LIABILITIES AND EQUITY | ||||||
| Liabilities | ||||||
| Current Liabilities | ||||||
| Accounts payable and accrued liabilities, including: | 20,035 | 21,126 | 15,251 | |||
| Employee-related liabilities | ✕ | ✕ | ✕ | 9,117 | ||
| Accounts payable | 3,032 | 4,805 | ||||
| Accrued liabilities | 20,035 | 21,126 | ||||
| Other undisclosed accounts payable and accrued liabilities | (3,032) | (4,805) | 6,134 | |||
| Deferred revenue | 22,695 | 12,986 | 7,081 | |||
| Debt | 580 | |||||
| Other liabilities | 7,903 | 7,960 | 6,352 | |||
| Other undisclosed current liabilities | 5,593 | 6,388 | 4,497 | |||
| Total current liabilities: | 56,226 | 49,040 | 33,181 | |||
| Noncurrent Liabilities | ||||||
| Liabilities, other than long-term debt | 43,519 | 42,619 | 24,739 | |||
| Deferred revenue | 15,132 | 13,124 | 9,790 | |||
| Estimated litigation liability | 16,477 | 15,596 | 13,745 | |||
| Other liabilities | 2,431 | 1,587 | 1,204 | |||
| Operating lease, liability | 9,479 | 12,312 | ||||
| Other undisclosed noncurrent liabilities | 1,648 | 2,271 | ||||
| Total noncurrent liabilities: | 45,167 | 44,890 | 24,739 | |||
| Total liabilities: | 101,393 | 93,930 | 57,920 | |||
| Equity | ||||||
| Equity, attributable to parent, including: | 393,064 | 425,546 | 405,385 | |||
| Common stock | 131 | 135 | 126 | |||
| Additional paid in capital | 423,386 | 442,887 | 423,625 | |||
| Accumulated other comprehensive income (loss) | (1,275) | (697) | 897 | |||
| Accumulated deficit | (29,178) | (17,030) | (19,606) | |||
| Other undisclosed equity, attributable to parent | 251 | 343 | ||||
| Total equity: | 393,064 | 425,546 | 405,385 | |||
| TOTAL LIABILITIES AND EQUITY: | 494,457 | 519,476 | 463,305 | |||
Income Statement (P&L) ($ in thousands)
| 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | ||
|---|---|---|---|---|---|
| Revenues | 193,015 | 164,036 | 127,950 | ||
| Cost of revenue (Cost of Product and Service Sold) | (83,589) | (63,062) | (48,806) | ||
| Gross profit: | 109,426 | 100,974 | 79,144 | ||
| Operating expenses | (137,271) | (102,778) | (69,987) | ||
| Operating income (loss): | (27,845) | (1,804) | 9,157 | ||
| Nonoperating income (expense) | 12,136 | 3,064 | (3,219) | ||
| Investment income, nonoperating | 6,413 | 4,619 | 49 | ||
| Other nonoperating income (expense) | 7,794 | 1,018 | (1,527) | ||
| Interest and debt expense | (2,071) | (2,573) | (1,741) | ||
| Income (loss) from continuing operations before equity method investments, income taxes: | (17,780) | (1,313) | 4,197 | ||
| Other undisclosed income (loss) from continuing operations before income taxes | 2,071 | 2,573 | 1,741 | ||
| Income (loss) from continuing operations before income taxes: | (15,709) | 1,260 | 5,938 | ||
| Income tax expense (benefit) | 3,561 | 1,224 | (2,911) | ||
| Income (loss) from continuing operations: | (12,148) | 2,484 | 3,027 | ||
| Income before gain (loss) on sale of properties: | ✕ | ✕ | ✕ | 3,027 | |
| Net income (loss): | (12,148) | 2,484 | 3,027 | ||
| Net loss attributable to noncontrolling interest | (92) | (26) | |||
| Other undisclosed net income attributable to parent | 92 | 26 | |||
| Net income (loss) attributable to parent: | (12,148) | 2,484 | 3,027 | ||
| Undistributed earnings (loss) allocated to participating securities, basic | 3,001 | ||||
| Other undisclosed net income available to common stockholders, basic | 92 | ||||
| Net income (loss) available to common stockholders, diluted: | (12,148) | 2,576 | 6,028 | ||
Comprehensive Income ($ in thousands)
| 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | ||
|---|---|---|---|---|---|
| Net income (loss): | (12,148) | 2,484 | 3,027 | ||
| Comprehensive income (loss): | (12,148) | 2,484 | 3,027 | ||
| Comprehensive income (loss), net of tax, attributable to noncontrolling interest | (236) | 92 | (317) | ||
| Other undisclosed comprehensive income (loss), net of tax, attributable to parent | (342) | (1,686) | 1,149 | ||
| Comprehensive income (loss), net of tax, attributable to parent: | (12,726) | 890 | 3,859 | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.